Indeed, sPLA2 acts as a prominent immune‐lipidomic hub, discriminates between moderate and severe sepsis in COVID‐19 and links eicosanoids to multiple inflammatory proteins and to clinical markers of disease severity. Here, PLA2G2A is linked to Sepsis.